Rifaximin

Generic Name: Rifaximin

Brand Names: Xifaxan, Zaxine

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₁N_₃O_₁₁

CAS Number: 80621-81-4

Unique Ingredient Identifier: L36O5T016N

Background: Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...

Indication: Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...

Associated Conditions: Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea

Associated Therapies: -

Clinical Trials

Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Phase 3

Completed

Conditions: Ascites
Cirrhosis
Peritonitis

Interventions: Drug: Rifaximin
Other: Placebo

First Posted Date: 2017-03-03

Last Posted Date: 2024-03-05

Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Target Recruit Count: 160

Registration Number: NCT03069131

Locations: 🇫🇷
Hôpital Jean Verdier, Bondy, France
🇫🇷
CHU de Reims, Reims, France
🇫🇷
CHU Amiens, Amiens, France

and more 15 locations

Rifaximin in Patients With Gastroesophageal Variceal Bleeding

Not Applicable

Completed

Conditions: Esophageal and Gastric Varices
Gastrointestinal Hemorrhage
Cirrhosis

Interventions: Drug: Rifaximin

First Posted Date: 2016-12-13

Last Posted Date: 2018-05-11

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 80

Registration Number: NCT02991612

Locations: 🇨🇳
180 Fenglin Road, Shanghai, Shanghai, China

Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding

Not Applicable

Conditions: Esophageal and Gastric Varices
Cirrhosis
Gastrointestinal Hemorrhage

Interventions: Drug: Rifaximin

First Posted Date: 2016-11-16

Last Posted Date: 2016-11-16

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 308

Registration Number: NCT02964195

Locations: 🇨🇳
180 Fenglin Road, Shanghai, Shanghai, China

Metabolic Consequences of Gastrointestinal Surgery

Not Applicable

Terminated

Conditions: Gastrectomy
Oesophagectomy
Dumping Syndrome
Hypoglycaemia

Interventions: Drug: Somatostatin
Drug: Rifaximin

First Posted Date: 2016-07-19

Last Posted Date: 2019-04-02

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 81

Registration Number: NCT02836353

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom

Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

Early Phase 1

Withdrawn

Conditions: End Stage Renal Disease

Interventions: Drug: Rifaximin

First Posted Date: 2016-04-14

Last Posted Date: 2019-02-28

Lead Sponsor: Jason Stubbs, MD

Registration Number: NCT02738905

Locations: 🇺🇸
Westwood Dialysis Center, Westwood, Kansas, United States
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea

Phase 2

Conditions: Irritable Bowel Syndrome

Interventions: Drug: Rifaximin
Procedure: Fecal microbiota transplantation

First Posted Date: 2016-01-11

Last Posted Date: 2021-12-30

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 10

Registration Number: NCT02651740

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China

GutHeart: Targeting Gut Microbiota to Treat Heart Failure

Phase 2

Conditions: Systolic Heart Failure

Interventions: Drug: Rifaximin
Drug: Saccharomyces boulardii

First Posted Date: 2015-12-22

Last Posted Date: 2019-03-26

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 150

Registration Number: NCT02637167

Locations: 🇳🇴
Oslo University Hospital - Rikshospitalet, Oslo, Norway

Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease

Phase 2

Terminated

Conditions: Crohn Disease
Adherent-invasive E. Coli

Interventions: Drug: Ciprofloxacin
Drug: Ciprofloxacin Placebo
Drug: Rifaximin
Drug: Rifaximin Placebo

First Posted Date: 2015-12-02

Last Posted Date: 2023-08-23

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 24

Registration Number: NCT02620007

Locations: 🇫🇷
Kremlin-Bicetre hospital, Le Kremlin-Bicêtre, France
🇫🇷
Gastroenterology department, Le Kremlin Bicetre, France

Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices

Phase 3

Conditions: Liver Cirrhosis
Portal Hypertension

Interventions: Drug: Placebo
Drug: Rifaximin

First Posted Date: 2015-07-27

Last Posted Date: 2015-07-28

Lead Sponsor: University of Padova

Target Recruit Count: 60

Registration Number: NCT02508623

Locations: 🇮🇹
Azienda Ospedaliera di Padova, Padua, Italy

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

Phase 3

Completed

Conditions: Diarrhea

Interventions: Drug: Placebo Tablet
Drug: Xifaxan®
Drug: Rifaximin

First Posted Date: 2015-07-15

Last Posted Date: 2019-12-05

Lead Sponsor: Actavis Inc.

Target Recruit Count: 739

Registration Number: NCT02498418

Locations: 🇺🇸
Site 1, Coral Gables, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy